<DOC>
	<DOCNO>NCT00344422</DOCNO>
	<brief_summary>The purpose study determine well newly diagnose multiple myeloma patient respond experimental regimen Vincristine , DOXIL ( doxorubicin HCl liposome injection ) Dexamethasone ( VDD ) versus standard treatment Vincristine , Doxorubicin Dexamethasone ( VAD ) .</brief_summary>
	<brief_title>Vincristine , DOXIL ( Doxorubicin HCl Liposome Injection ) Dexamethasone vs. Vincristine , Doxorubicin , Dexamethasone Patients With Newly Diagnosed Multiple Myeloma</brief_title>
	<detailed_description>This randomize , open label study compare efficacy , clinical benefit , toxicity safety combination Vincristine , DOXIL® ( doxorubicin HCl liposome injection ) , Dexamethasone ( VDD ) standard regimen Vincristine , Doxorubicin Dexamethasone ( VAD ) patient newly diagnose multiple myeloma . Approximately 200 patient newly diagnose multiple myeloma randomize receive either VDD VAD . This study determine compare objective response rate ( percentage patient attain Objective Status Complete Remission , Remission Partial Remission ) patient receive VDD vs. VAD . This study also evaluate compare clinical benefit VDD vs. VAD follow measure : Hospitalization ; Documented sepsis ; Antibiotic use ; Grade 3 4 neutropenia neutropenic fever . VDD : Vincristine 1.4 mg/m2 IV Day 1 ; Doxil® 40 mg/m2 IV Day 1 ; Dexamethasone 40 mg/day oral Days 1-4 ; VAD : Vincristine 0.4 mg/day continuous infusion Days 1-4 ; Doxorubicin 9.0 mg/m2/day continuous infusion Days 1-4 ; Dexamethasone 40 mg/day orally Days 1-4 ; Every 28 day 4 cycle</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Untreated multiple myeloma require treatment Total cumulative dose prior doxorubicin exceed 240 mg/m2 Must measurable disease Left Ventricular Ejection Fraction ( LVEF ) &gt; = 50 % determined Multiple Gated Acquisition Scan ( MUGA ) Karnofsky performance status &gt; = 60 % Adequate bone marrow , liver renal function Diseasefree prior malignancy &gt; = 5 year exception basal cell squamous cell carcinoma skin carcinoma situ cervix Female participant ( child bear potential sexually active ) male participant ( sexually active partner childbearing potential ) must use medically acceptable method birth control . Life expectancy &gt; = 3 month Pregnant breast feed History cardiac disease , New York Heart Association Class II great , congestive heart failure unstable angina , uncontrolled hypertension cardiac arrythmias myocardial infarction within last 6 month Uncontrolled diabetes mellitus systemic infection Nonsecretory myeloma , Monoclonal Gammopathy Unknown Significance ( MGUS ) smolder myeloma Confusion , disorientation , history psychiatric illness may impair patient 's ability give inform consent Prior chemotherapy treat Multiple Myeloma Prior radiotherapy area great 1/3 skeleton Prior local radiotherapy within 1 week treatment Any investigational agent within 30 day first dose treatment Prior single agent dexamethasone ( another corticosteroid ) treat Multiple Myeloma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Anthracyclines</keyword>
	<keyword>Liposomes</keyword>
	<keyword>Liposomal</keyword>
	<keyword>Vincristine</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Pegylated Liposomal Doxorubicin</keyword>
	<keyword>DOXIL</keyword>
	<keyword>drug resistant myeloma</keyword>
</DOC>